U.S., July 23 -- ClinicalTrials.gov registry received information related to the study (NCT07720466) titled 'Salivary Function and Dental Changes During GLP-1 Therapy' on July 14.
Brief Summary: People who use glucagon-like peptide-1 (GLP-1) receptor agonists, such as semaglutide and tirzepatide, may experience changes in their oral health. Some people report dry mouth, changes in saliva, and increased wear of their teeth after starting these medicines. However, little is known about whether these medicines affect saliva and dental hard tissues.
The purpose of this study is to evaluate changes in salivary calcium levels, salivary function, and dental hard tissues in adults who begin treatment with semaglutide or tirzepatide for obesity.
...